Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivorsSARS-CoV-1 생존자의 COVID-19 추가 백신에 대한 항체 및 T세포 반응Article Published on 2022-11-012022-11-15 Journal: Clinical immunology (Orlando, Fla.) [Category] SARS, 백일해, 진단, 파상풍, [키워드] acute respiratory syndrome Antibody titer Beta booster booster vaccination Booster vaccine CD4 CD8 comparable coronavirus COVID-19 Delta dose effective elicit elicited generate healthy individual humoral immune response less MOST naïve neutralization neutralizing antibody omicron robust SARS-CoV-1 SARS-CoV-1 survivors SARS-CoV-2 survivor Survivors T cell response T cell responses T-cell Response WA1 while Wuhan-Hu-1 [DOI] 10.1016/j.clim.2022.109103 PMC 바로가기
B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patientsArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95% CI 95% confidence interval Affect anti-CD20 anti-CD20 treatment antibody Antibody Response Antibody titers B cell B cells B-cell B-cell depletion Blood booster cellular response Cohort correlated detectable develop Efficacy Guidance humoral identify IgG^{+} interleukin-13 Logistic regression median memory multiple sclerosis naïve no correlation Odds ratio Patient patients predict predictor Probability recent rituximab S1 domain SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Seroconversion T-cell Response treated Treatment turn vaccination vaccine responses [DOI] 10.1111/ene.15492 PMC 바로가기
Concordance of B- and T-cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19Article Published on 2022-11-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 진단, [키워드] absence Analysis anti-IgG antibodies antibody Antibody titer Cellular immune response cellular immunity Cohort correlated correlated strongly COVID COVID-19 COVID-19 pandemic ELISA Evidence Final First wave IgG individual pandemic participant positive antibody response Regulatory response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 peptide SARS-CoV2 infection spike Symptom symptom response. symptomatic and asymptomatic T cell T-cell T-cell Response TwinsUK were assessed [DOI] 10.1002/jmv.28016 PMC 바로가기
Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasiasArticle Published on 2022-11-012022-11-15 Journal: British Journal of Haematology [Category] 진단, [키워드] age anti-CD38 antibodies antibody Antibody Response Antibody testing antibody titres Antigen binding domain BNT162b2 breadth Cell comparable coronavirus disease correlated COVID-19 COVID-19 vaccination demonstrated detectable dose dyscrasia elicit Genome healthy humoral immune immunization Immunocompromised Immunoglobulin Increasing initial Intervention investigated JNJ-78436735 maturation median mRNA vaccine mRNA-1273 Myeloma of BNT162b2 Patient patient population plasma Population proportion receiving Region response spike-specific T-cell Spike-specific T-cell responses Surface glycoprotein T-cell T-cell receptor T-cell Response TCR tested therapy underlying disease vaccination Vaccines [DOI] 10.1111/bjh.18434 PMC 바로가기
Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2Article Published on 2022-11-012022-11-15 Journal: Cellular and Molecular Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] A570D A701V addition Affect affected antibodies antigenicity B.1.1.529 B.1.1.7 B.1.1.7 lineage B.1.351 B.1.617.2 BALB/c mice binding circulating cross-neutralization activity D1118H decrease Del Delta determine DNA vaccine Effects Efficiency elicited humoral immune response immune evasion immunized immunogen in vitro investigated K417N L18F Lineage Mutation NAbs Naturally neutralization Neutralizing Neutralizing antibodies neutralizing antibody NTD omicron opposite overcome P681H Pseudotyped viruses reduced S982A SARS-CoV-2 SARS-CoV-2 variant sera significantly increased single mutation single mutations spike mutation T cell T cell responses T-cell Response T716I tested the RBD Transmissibility unlikely Vaccine vaccine immunogenicity variants of concern viral entry viral infectivity VoC VOCs was determined weakened [DOI] 10.1038/s41423-022-00924-8 PMC 바로가기
Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine RecipientsArticle Published on 2022-10-292022-11-15 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE2 acute respiratory syndrome antibodies antibody binding coronavirus coronavirus 2 COVID-19 individual inhibited levels of antibody messenger Messenger RNA no difference omicron recipient recipients respiratory response responses against RNA SARS-CoV-2 significantly lower Spike protein T cells T-cell Response T-cell responses Vaccine vaccine strain variant while [DOI] 10.1093/cid/ciac305 PMC 바로가기
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyArticle Published on 2022-10-272022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Ad26.COV2.S Ad26.COV2.S vaccine age Analysis anti-SARS-CoV-2 Anti-spike antibody Antibody Response Antiretroviral therapy approved assays BNT162b2 CD4+ T-cell CD8+ T-cell ChAdOx1-S comparable Concentration conducted Control controls COVID-19 defined ELISPOT Endpoint Environment Final generally mild geometric HIV HIV-negative IFN-γ immunogenic immunogenicity Increased IQR less maintain male marker median age mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based vaccines Netherland Netherlands of BNT162b2 PLWH predicted primary endpoint prospective cohort study Public reactogenicity receiving recipients reduced Registered remained required response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 spike peptide SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Serious Adverse Events serological response Sex suppressed T-cell Response the median the vaccine Trial vaccination Vaccine vaccine group Viral load with HIV [DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
Construction and evaluation of a self-replicative RNA vaccine against SARS-CoV-2 using yellow fever virus repliconArticle Published on 2022-10-202022-11-15 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome antibody Antigen C57BL/6 caused cells co-expressed construction coronavirus coronavirus disease COVID-19 effective vaccine Efficacy Electroporation elicit ENCODE ENhance evaluated Fever gene encoding Host host genome immune response Immunity IMPROVE Infection Innate immunity kidney mice mRNA vaccine pandemic Protein qRT-PCR Replication replicon responses RNA RNA vaccine robust S protein expression Safe SARS-CoV-2 significantly higher single dose Specific T-cell response T-cell Response the S protein Vaccine vaccine administration vaccine platform virus [DOI] 10.1371/journal.pone.0274829 PMC 바로가기
Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses’ Vaccinated Solid Organ Transplant RecipientsArticle Published on 2022-10-192022-11-15 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] administration analyzed booster booster dose booster doses Breakthrough infection cellular response CLIA Cohort COVID-19 dose Efficacy ELISA ELISpot assay fourth dose General population humoral IgA IgA level IgG immune immune response IMPROVE in both group Infection mRNA mRNA vaccine natural natural infection new SARS-CoV-2 no difference Organ transplant Patient positive recipient recipients repeated response SARS-CoV-2 SARS-COV-2 infection secretion serum IgG severe COVID-19 significant increase significantly increased Solid solid organ transplant Solid organ transplant recipients Still T cell T-cell T-cell Response Transplant vaccination Vaccine vaccine-induced immune response variants of concern [DOI] 10.3390/v14102299 PMC 바로가기
Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infectionArticle Published on 2022-10-172022-11-15 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, [키워드] assays BNT162b2 BNT162b2 vaccine class correlated demonstrated develop dose doses epitope exhibited Frequency greater healthcare worker healthy IFN-γ IgG response IL-2 IL2 Immunity individual infected with SARS-CoV-2 Infection Interferon-gamma interleukin-2 magnitude Moderna mRNA-1273 vaccine mononuclear cell mRNA-1273 N and M nine participant Participants PCR testing peptide Peripheral blood Pfizer-BioNTech positive Post-infection Proteins proteome repeated responders response responses against robust S glycoprotein S1 and S2 S2 subunit SARS-CoV-2 SARS-COV-2 infection structural protein subunit subunits T cell response T-cell Response the SARS-CoV-2 uninfected vaccination vaccinee was determined were expressed with COVID-19 [DOI] 10.1371/journal.pone.0276241 PMC 바로가기